Table 1.
Clinical and pathological features of the study population
| Total | OPIODS | NO OPIODS | p | ||
|---|---|---|---|---|---|
| N. (%) | N. (%) | N. (%) | |||
| 193 (100) | 42 (100) | 151 (100) | |||
| Sex | |||||
| Male | 120 (62) | 25 (60) | 95(63) | 0.689 | |
| Female | 73 (38) | 17 (40) | 56 (37) | ||
| Age (years) | |||||
| Median | |||||
| < 65 | 61 (32) | 14 (33) | 47 (31) | ||
| 65–75 | 78 (40) | 21 (50) |
57 (38) 57 (38) |
||
| > 75 | 53 (53) | 7 (17) | 46 (31) | 0.171 | |
| Missed | 1 (1) | ||||
| Diagnosis | |||||
| NSCLC | 59 (30) | 21(62) | 33 (22) | < 0.0001 | |
| Melanoma | 99 (51) | 7 (17) | 92 (61) | ||
| Renal Cancer | 28 (14) | 5 (12) | 23 (15) | ||
| Urothelial Cancer | 5 (3) | 3 (7) | 2 (1) | ||
| Merkel Tumor | 1 (0.5) | 1 (2) | 0 | ||
| Colon Cancer | 1 (0.5) | 0 | 1 (1) | ||
| ECOG PS | |||||
| 0 | 94 (49) | 9 (21) | 85 (56) | ||
| ≥1 | 99 (51) | 33 (79) | 66 (44) | < 0.0001 | |
| Comorbidity | |||||
| 0–1 | 122 (63) | 29 (69) | 93 (62) | 0.375 | |
| ≥2 | 71 (37) | 13 (31) | 58 (38) | ||
| Immunotherapy, drug name | |||||
| Nivolumab | 121 (63) | 26 (62) | 95 (63) | 0.145 | |
| Pembrolizumab | 60 (31) | 11 (26) | 49 (32) | ||
| Atezolizumab | 11 (6) | 4 (10) | 7 (5) | ||
| Avelumab | 1 (0.5) | 1 (2) | 0 | ||
| Immunotherapy setting | |||||
| First line | 91 (47) | 11 (26) | 80 (53) | ||
| Second line | 69 (36) | 21 (50) | 48 (32) | 0.009 | |
| Beyond II-line | 33 (17) | 10 (24) | 23 (15) | ||
| Antibiotics/Antifungals | |||||
| Yes | 21 (11) | 8 (19) | 13 (9) | 0.055 | |
| Not | 172 (89) | 34 (81) | 138 (91) | ||
| Corticosteroids | |||||
| Yes | 44 (23) | 20 (48) | 24 (16) | < 0.0001 | |
| Not | 148 (77) | 22 (52) | 126 (84) | ||
| Opiods | |||||
| Yes | 42 (22) | - | - | ||
| Not | 151 (78) | - | - | ||
| Tumor burden | |||||
| Low | 91 (47) | 12 (29) | 79 (52) | ||
| High | 102 (53) | 30 (71) | 72 (48) | 0.006 | |
PS ECOG performance status, NSCLC non-small cell lung cancer, RCC renal cell carcinoma